Myelodysplasia and acute myeloid leukaemia in cases of aplastic anaemia and congenital neutropenia following G-CSF administration.
Myelodysplasia and acute myeloid leukaemia (MDS/AML) developed in three cases of severe aplastic anaemia (SAA) and one case of congenital neutropenia (CN, Kostmann's disease) who received recombinant human granulocyte colony-stimulating factor (G-CSF) are reported. In these four MDS/AML cases, age at diagnosis of SAA/CN was 0-13 years, the cumulative dose of G-CSF was 98 micrograms/kg to 10 mg/kg over 1-57 months, and the interval from initiation of G-CSF to MDS/AML was 25, 23, 31 and 57 months, respectively. These results suggest a link between SAA/CN and MDS/AML in relation to G-CSF administration; however, large studies are necessary to determine if such a risk is significant in patients with SAA/CN who are treated with G-CSF.
Imashuku
S
S
Division of Paediatrics, Children's Research Hospital, Kyoto Prefectural University of Medicine, Japan.
Hibi
S
S
Kataoka-Morimoto
Y
Y
Yoshihara
T
T
Ikushima
S
S
Morioka
Y
Y
Todo
S
S
D000293:Adolescent; D000741:Anemia, Aplastic / Q000150:complications*; D000754:Anemia, Refractory, with Excess of Blasts / Q000209:etiology*; D002471:Cell Transformation, Neoplastic; D002675:Child, Preschool; D005500:Follow-Up Studies; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects*; D006801:Humans; D007223:Infant; D015479:Leukemia, Myelomonocytic, Acute / Q000209:etiology*; D009503:Neutropenia / Q000150:complications / Q000151:congenital*; D011994:Recombinant Proteins / Q000009:adverse effects
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor